Semax

Semax is a lab-made peptide (a short chain of amino acids, the building blocks of proteins) that was developed in Russia in the late 1980s. Doctors there prescribe it for stroke and for problems with thinking and memory. It is not approved anywhere in the West, and most of the research on it is written in Russian.

What it is

Semax is a heptapeptide (a peptide made of seven amino acids) with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It is a copy of a small piece of a natural hormone called adrenocorticotropic hormone, or ACTH (the part used is the section labeled 4-10). Scientists tweaked it by adding a short proline-glycine-proline “tail” so the body breaks it down more slowly. It first showed up in the scientific literature around 1991 and is usually given as a nasal spray (intranasally, meaning through the nose). In Russia it is a registered medicine that appears on the country’s List of Vital and Essential Drugs, prescribed for ischemic stroke (a stroke caused by a blocked blood vessel in the brain), other blood-flow problems in the brain, trouble with thinking and memory, and some conditions affecting the optic nerve (the nerve that connects the eye to the brain).

The claims

Online, Semax is sold as a “nootropic” (a substance claimed to boost mental performance). Sellers say it sharpens focus, memory, and motivation; protects or repairs brain cells after a stroke; and eases anxiety and low mood. The most common claim about how it works is that it quickly raises a protein called brain-derived neurotrophic factor, or BDNF, which helps the brain form and reshape connections between cells.

What the evidence actually shows

The idea of how it works is reasonable, but it hasn’t been fully nailed down. Animal studies do show that Semax can raise BDNF and its docking site (the TrkB receptor), and can affect dopamine and serotonin, two brain chemicals that influence mood and motivation. It may also act on melanocortin receptors or slow down the enzymes that break peptides apart. Exactly how it works in people is still unclear.

There is some human data, but not much. The strongest studies are small Russian stroke trials. One controlled trial, run during the early days after a stroke that affected one side of the brain, gave Semax to 30 patients and compared them with 80 patients on standard treatment. It reported some effect on how quickly people recovered, but it didn’t clearly explain how patients were assigned to groups (randomization) or whether anyone was kept unaware of who got the drug (blinding) — both of which help keep a study fair. Other small studies report better movement scores, higher BDNF in the blood, and improved scores on the Barthel index (a common scale for how well someone can handle daily activities). The claims about thinking and mood rest on small studies in volunteers — for example, changes in brain-wave readings (EEG) and better scores on memory tests — and on decades of Russian clinical use, rather than on large, blinded, peer-reviewed trials. There are no published Western randomized controlled trials (the gold-standard study design), no long-term safety studies, and a lot of the research has never been translated. So the picture is promising, but not settled.

Legal and regulatory status

Semax is not approved by the FDA, the EMA (Europe’s drug regulator), or other Western regulators for any use. In the United States, its standing under the rules for compounding (where a pharmacy mixes a custom medicine) has been shifting. In 2023 the FDA put Semax in “Category 2” — a list of bulk ingredients it felt raised real safety concerns for compounding under a rule called section 503A. In April 2026 the agency said Semax (along with several other peptides) was being taken off Category 2 because the original requests to review it had been withdrawn. Here’s the important part: being removed from Category 2 does not, on its own, give a green light to compound it. Semax has not been added to the approved “503A bulks list,” and the FDA has not said it will hold off on enforcement. The FDA’s Pharmacy Compounding Advisory Committee is set to discuss whether Semax (both the free base and acetate forms) should be added to the 503A bulks list at a public meeting on July 23-24, 2026 (Semax is on the July 24 agenda; Docket FDA-2026-N-2979). As of this writing, no decision has been made. Semax is also widely sold online as a “research chemical,” which is not a legal way to use it in people.

For athletes: Semax is not listed by name on the WADA Prohibited List, but because no government health authority anywhere has approved it for human use, it falls under category S0 (Non-Approved Substances), which is banned at all times. Under “strict liability,” an athlete is responsible for whatever turns up in their system.

Safety

Decades of Russian clinical use, plus small studies, suggest Semax is generally well tolerated in the short term, with few reported side effects. But there is no solid long-term safety data, no Western regulatory review, and real doubt about how pure the material sold online actually is. Treat the safety picture as incomplete.

Bottom line

Semax has a longer real-world track record than most “research” peptides, and it has some genuine human data behind it. But the trials are small, mostly in Russian, and weak by today’s standards. The possible benefits for thinking and stroke recovery are plausible and partly supported — not proven. This is not medical advice.

Evidence grade: 6/10 · Preliminary.

Sources

• Semax - Wikipedia
• Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study) - PubMed
• Semax in prevention of disease progress and development of exacerbations in patients with cerebrovascular insufficiency - PubMed
• Semax and Pro-Gly-Pro Activate the Transcription of Neurotrophins and Their Receptor Genes after Cerebral Ischemia - PMC
• Pharmacy Compounding Advisory Committee; Notice of Meeting; Bulk Drug Substances Nominated for the 503A List - Federal Register
• FDA considers adding a dozen peptides to its bulk drug compounding list - RAPS
• What FDA’s Latest Actions Mean for Peptide Compounding - National Law Review
• The Prohibited List - World Anti-Doping Agency
• WADA Prohibited List - USADA
• FDA Pharmacy Compounding Advisory Committee, July 23-24, 2026 meeting announcement